Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. - Wikidata - wikimedia - TriplyDB

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

http://www.wikidata.org/entity/Q36077514

about

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up Paraneoplastic syndromes: an approach to diagnosis and treatment.Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis Current and emerging therapies for the treatment of myasthenia gravis.High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease Treatment of myasthenia gravis based on its immunopathogenesis Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.Clinical characteristics of refractory myasthenia gravis patients.Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.Autoimmune myasthenia gravis.Treatment strategies for myasthenia gravis.Diagnostic use of autoantibodies in myasthenia gravis.High-dose chemotherapy and multiple sclerosis.Treatment of myasthenia gravis: focus on pyridostigmine.Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.Overcoming challenges in the diagnosis and treatment of myasthenia gravis.Diagnostic and therapeutic strategies for management of autoimmune encephalopathies.Myasthenia gravis: recent advances in immunopathology and therapy.Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies.Overview of myasthenia gravis.Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.Efficacy and Safety of the TCM Qi-Supplementing Therapy in Patients with Myasthenia Gravis: A Systematic Review and Meta-Analysis.When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.Treatment of MuSK-Associated Myasthenia Gravis.Management challenges in muscle-specific tyrosine kinase myasthenia gravis.

P2860

Q26765172-5F054709-92D7-4AE7-BBC9-A24478852BF1 Q33747331-EA3E6BBA-F8F0-47C2-AE44-5329C7A77F51 Q34135478-FCEBBA3C-9614-4046-A6A5-A6C1E0271E36 Q34409273-F6C42D9E-467B-4036-A4C3-35886B6A9777 Q34755933-63AAC454-C94B-4D4A-9FB7-1A27CC17524F Q34879129-90AF64F9-029B-4893-8478-9E35C38E8E42 Q34986999-600872B9-8886-4488-BD8C-5C379EE0D160 Q35322297-0B5F0977-BAA8-4973-BCEB-BA0D8D7F3831 Q35675970-F0E75671-9115-4AB2-84CB-20858942832B Q36562866-FEFAA30D-224B-409A-95A1-4C43B65D7AB0 Q36730633-573B0284-A7E9-4270-B4B3-0C54B16F5E9C Q36896003-15EE0D12-CBAE-4A4D-9A6A-1630885A56EC Q37315963-4BDAC45C-008A-46CC-888F-49C92A65F5AA Q37344993-6D7947C3-C864-4108-812F-3CBA92B05413 Q37409490-1946EBA0-8C5C-40A7-AC92-958F5031FCBC Q37483922-4BE4C3F5-9E75-406F-964B-07C361AC389D Q37727987-CBD8FD6C-9779-4833-87A4-886B478C9147 Q37822255-98F31F83-6FF0-47A7-A616-D4064CE51853 Q37911501-62925F76-A11E-4503-8DD6-1FEAA94DCE5A Q38259495-4499811F-F12E-452E-9372-00BD25471D2B Q38671442-55FCD13F-ECF8-4CAF-9AEE-6A42901E72CC Q38832800-9C752DED-61A5-4F0B-865A-5D1719FBDC86 Q38969032-DB8FC8AF-B393-4C37-BCB9-92D745DC6B73 Q39214015-089CAE5C-FE60-4A1B-BAE8-6F477C25BE44 Q41814408-3E6B2893-1217-4002-8707-4210B1677EE6 Q44367084-B5926B9E-1C02-4A96-84BA-65F5DEF4A200 Q47225363-B2BD5F59-6EFE-4B67-A286-0A8B765D102E Q48247212-537AA5B3-BEBB-483B-A62A-71933462D333 Q49280339-DBD1A3CF-B2A4-480F-9481-CA37E3FEFF4B Q54379059-FD9C51E3-2674-484C-99BE-DAEAC76D10F2 Q54464610-F2320886-7E44-4C1E-95A2-BDB95B99F691

P2860

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

http://www.wikidata.org/entity/Q36077514

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Rebooting the immune system wi ...... refractory myasthenia gravis.

@ast

Rebooting the immune system wi ...... refractory myasthenia gravis.

@en

type

label

Rebooting the immune system wi ...... refractory myasthenia gravis.

@ast

Rebooting the immune system wi ...... refractory myasthenia gravis.

@en

prefLabel

Rebooting the immune system wi ...... refractory myasthenia gravis.

@ast

Rebooting the immune system wi ...... refractory myasthenia gravis.

@en

P1433

Q36077514-88F31382-EACA-4658-9ABA-E694F8AC5413

P1476

Q36077514-E3722376-0883-47C9-8846-D55BF4CB84FC

P2093

Q36077514-12A3F6F5-F330-41A9-B382-D66328554386

Q36077514-20E1CC4F-DF40-442B-8E5E-B31F735CD212

Q36077514-7AB7AED3-23EF-4CAC-AE2B-15D0F55486B9

Q36077514-ABF142EA-DF5A-4479-98D0-605B0A915970

Q36077514-BB6EE492-6275-48CE-AB0D-26BA0A27508C

P2860

Q36077514-0127EF20-60EE-4DD9-98B0-E1D3D0A9218C

Q36077514-279D861A-4925-4AFB-BD92-0107A85040A9

Q36077514-4E1E0B99-7513-41CE-93E1-45075F0A08EB

Q36077514-4FB89415-CBBD-4F4D-9C80-3631317725DD

Q36077514-6419BB04-307F-4083-ABBC-D8D4EDEE4AF0

Q36077514-6C9B10F1-38C9-486B-8761-17FA283F08DF

Q36077514-7552A572-3D28-4EF4-B641-03A9999F2DF3

Q36077514-89CCA476-2B74-4D51-A1E6-F59F97C025E0

Q36077514-940595DF-06C8-4839-B4B9-4874E32435E3

Q36077514-A9441B76-D56B-47F5-A477-E895E2E05A1F

P304

Q36077514-583E3EC8-7869-4F06-B5CA-9227CFC35FDE

P31

Q36077514-64B484F5-7B10-4212-9DD4-C01C07E02C12

P356

Q36077514-0EC41CC0-F09D-4A7F-83B3-A675AB66AD09

P407

Q36077514-E621C1DE-F3D2-4741-A6F9-CB4406CBDEB6

P478

Q36077514-C86B9015-D1D9-4E2C-94B8-DF8E5CE4B055

P577

Q36077514-D2903846-13E7-44B7-B891-380DEBC3A26F

P5875

Q36077514-F1457005-6BDD-446B-AE93-837E7C4B1A9F

P698

Q36077514-3F95B539-20B1-4750-B6D8-7B26CDA68453

P921

Q36077514-F6FDB202-0E56-4458-9AEA-E3291BC26273

P932

Q36077514-5F3E4B6E-6C94-4E6B-B7CD-E090D309D421

P356

ANNALS.1405.033

P1433

Annals of the New York Academy of Sciences

P1476

Rebooting the immune system wi ...... refractory myasthenia gravis.

@en

P2093

Daniel B Drachman

http://www.w3.org/2001/XMLSchema#string

Richard J Jones

http://www.w3.org/2001/XMLSchema#string

Robert A Brodsky

http://www.w3.org/2001/XMLSchema#string

Robert N Adams

http://www.w3.org/2001/XMLSchema#string

Rong Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

Host-reactive CD8+ memory stem cells in graft-versus-host disease

Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis.

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells.

Quantification of T cell receptor rearrangement excision circles to estimate thymic function: an important new tool for endocrine-immune physiology.

High-dose therapy for autoimmune neurologic diseases.

Assessment of aldehyde dehydrogenase in viable cells.

Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.

P304

305-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1196/ANNALS.1405.033

http://www.w3.org/2001/XMLSchema#string

P407

P478

1132

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5288472

http://www.w3.org/2001/XMLSchema#string

P698

18567882

http://www.w3.org/2001/XMLSchema#string

P921

myasthenia gravis

P932

3390145

http://www.w3.org/2001/XMLSchema#string